Key result
Compound F-1 shows ~14-fold greater vasorelaxant potency than F-3 and lowers blood pressure in hypertensive rats.
Why the study?
The comparative vasomodulatory and antihypertensive effects of the tetrahydroisoquinoline derivatives F-1 and F-3 on the aorta and pulmonary artery required evaluation across in silico, in vitro, and in vivo models.
Do tetrahydroisoquinoline derivatives F-1 and F-3 induce vasorelaxation in isolated rat aortic and pulmonary artery smooth muscle and reduce blood pressure in adrenaline-induced hypertensive rats?
Do tetrahydroisoquinoline derivatives F-1 and F-3 induce vasorelaxation in isolated rat aortic and pulmonary artery smooth muscle and reduce blood pressure in adrenaline-induced hypertensive rats?
Answers are grounded in this paper and cite their sources.
Preclinical evaluation demonstrates that the tetrahydroisoquinoline derivative F-1 is a more potent vasorelaxant and antihypertensive agent than F-3, acting via L-type calcium channel blockade, adrenergic modulation, and partial nitric oxide pathways, though F-3 possesses a wider acute safety margin.
This study aimed to evaluate the vasomodulatory and antihypertensive effects of compounds 1-Phenyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride (F-1) and 1-(3′-hydroxyphenyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride (F-3) using an integrated approach combining in silico molecular docking, in vitro functional assays, and in vivo experimental models. Molecular docking analysis revealed that both compounds exhibit high binding affinity toward calcium-regulating targets, particularly the L-type calcium channel (Cav1.2), with binding energies of −8.2 kcal/mol (F1) and −8.1 kcal/mol (F3), indicating stable ligand–protein interactions and potential modulation of calcium influx. In vitro experiments demonstrated that both compounds significantly inhibited phenylephrine-induced vascular smooth muscle contraction in a concentration-dependent manner. F1 exhibited higher potency (IC₅₀ = 3.1×10⁻⁷ M) compared to F3 (IC₅₀ = 4.29×10⁻⁶ M), showing a more consistent and gradual inhibitory profile. Additionally, both compounds enhanced the vasorelaxant effect of verapamil and partially attenuated the inhibitory action of phentolamine, suggesting involvement in both calcium channel modulation and adrenergic signaling pathways. The reduction of their effects in the presence of L-NAME indicates partial dependence on nitric oxide-mediated mechanisms. In vivo studies in adrenaline-induced hypertensive rats demonstrated that F1 and F3 significantly reduced systolic and diastolic blood pressure in a dose- and time-dependent manner at doses of 10, 25, and 50 mg/kg. F1 showed a more pronounced antihypertensive effect, effectively restoring blood pressure toward physiological levels. Overall, the findings indicate that F1 is a more potent vasorelaxant and antihypertensive agent than F3. The observed effects are mediated through a multi-target mechanism involving inhibition of calcium influx, modulation of adrenergic signaling, and partial involvement of nitric oxide pathways. These results highlight F1 as a promising candidate for the development of novel therapeutic agents for the treatment of hypertension and vascular dysfunction. HIGHLIGHTS F1 and F3 demonstrated significant vasorelaxant activity in vitro and ex vivo models Both compounds inhibited KCl- and phenylephrine-induced vascular contractions in a concentration-dependent manner F1 exhibited higher potency and efficacy compared to F3 across all experimental conditions Vasorelaxant effects were partially independent of nitric oxide, as confirmed using L-NAME In vivo studies showed marked reductions in systolic and diastolic blood pressure F1 produced stronger and more sustained antihypertensive effects than F3 Molecular docking revealed high binding affinity to L-type (Cav1.2) and R-type calcium channels Interactions were mainly mediated by hydrophobic and π-related mechanisms Calcium channel modulation is a key mechanism underlying the observed pharmacological effects F1 is a promising candidate for further development as a cardiovascular therapeutic agent GRAPHICAL ABSTRACT
No takes yet. Share an insight, caveat, or question.
Sharifjanovna et al. (2026) studied Vascular smooth muscle contraction and hypertension (preclinical in vitro, in vivo, and in silico models). 1-Phenyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride (F-1) and 1-(3'-hydroxyphenyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride (F-3) vs. Control baseline contraction (30 mM or 15 uM KCl, 1 uM phenylephrine), verapamil (IC50 = 0.1 uM), phentolamine (IC50 = 0.1 uM), and L-NAME (1 uM) was evaluated on Inhibition of phenylephrine-induced and KCl-induced vascular smooth muscle contraction in isolated rat aortic and pulmonary artery rings (p=<0.05).
Synapse has enriched 10 related papers. Consider them for comparative context: